Recombinant Human Achaete-Scute Homolog 1 (ASCL1) Protein (His)

Beta LifeScience SKU/CAT #: BLC-01757P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Achaete-Scute Homolog 1 (ASCL1) Protein (His)

Beta LifeScience SKU/CAT #: BLC-01757P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Achaete-Scute Homolog 1 (ASCL1) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb P50553
Target Symbol ASCL1
Synonyms Class A basic helix-loop-helix protein 46
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His
Target Protein Sequence MESSAKMESGGAGQQPQPQPQQPFLPPAACFFATAAAAAAAAAAAAAQSAQQQQQQQQQQQQAPQLRPAADGQPSGGGHKSAPKQVKRQRSSSPELMRCKRRLNFSGFGYSLPQQQPAAVARRNERERNRVKLVNLGFATLREHVPNGAANKKMSKVETLRSAVEYIRALQQLLDEHDAVSAAFQAGVLSPTISPNYSNDLNSMAGSPVSSYSSDEGSYDPLSPEEQELLDFTNWF
Expression Range 1-236aa
Protein Length Full Length
Mol. Weight 29.6 kDa
Research Area Neuroscience
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Transcription factor that plays a key role in neuronal differentiation: acts as a pioneer transcription factor, accessing closed chromatin to allow other factors to bind and activate neural pathways. Directly binds the E box motif (5'-CANNTG-3') on promoters and promotes transcription of neuronal genes. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Plays a role at early stages of development of specific neural lineages in most regions of the CNS, and of several lineages in the PNS. Essential for the generation of olfactory and autonomic neurons. Acts synergistically with FOXN4 to specify the identity of V2b neurons rather than V2a from bipotential p2 progenitors during spinal cord neurogenesis, probably through DLL4-NOTCH signaling activation. Involved in the regulation of neuroendocrine cell development in the glandular stomach.
Subcellular Location Nucleus.
Database References

HGNC: 738

OMIM: 100790

KEGG: hsa:429

STRING: 9606.ENSP00000266744

UniGene: PMID: 29500235

  • a large subset of patient-derived glioblastoma stem cells (GSCs) express high levels of Achaete-scute homolog 1 (ASCL1), a proneural transcription factor involved in normal neurogenesis. PMID: 28712938
  • System analysis identified distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer. PMID: 28742165
  • Results indicate transcription factor Ascl1 protein functionalized with intracellular protein delivery technology (Ascl1-IPTD) as a powerful tool for engineering neural tissue from pluripotent stem cells. PMID: 27138845
  • knocking down achaete-scute complex homologue-1 expression could significantly suppress the proliferation, migration, and invasion of laryngeal carcinoma cell in vitro and disorder epithelial-mesenchymal transformation-associated protein expression. PMID: 28618959
  • we found that CpG_6.7.8 of the achaete-scute homolog 1 CpG island is frequently hypermethylated in early-stage pulmonary neuroendocrine tumors, and this aberrant hypermethylation is negatively correlated with achaete-scute homolog 1 expression in this tumor spectrum PMID: 28621224
  • the first comprehensive high-resolution information on the structural propensities and conformational dynamics of Ascl1, is reported. PMID: 28402879
  • ASCL1 expression may determine the cell behaviors of SCLC partly through modifying EMT phenotypes. PMID: 27785690
  • This report identifies novel roles for the transcription factor Ascl1 in enteric gliogenesis and neurogenesis PMID: 27076429
  • ASCL1 expression is regulated by BRD4 is frequently overexpressed in small cell lung cancer. PMID: 26253517
  • Data show that chrysin suppressed cell proliferation and reducing expression of achaete-scute complex-like 1 (ASCL1) and the neuroendocrine biomarker chromogranin A (CgA). PMID: 26403073
  • hASH1 is a specific marker to distinguish neuroendocrine tumors from squamous cell carcinomas and adenocarcinomas PMID: 26596584
  • marker for neurogenic potential in cultured retinal progenitor cells PMID: 26292211
  • Achaete-scute homolog 1 (ASCL1), a transcription factor required for proper development of pulmonary neuroendocrine cells, is essential for the survival of a majority of lung cancers with neuroendocrine features. PMID: 25267614
  • data suggest that a prominent down-regulation of hnRNP-A2/B1 during hypoxia is associated with the post-transcriptional suppression of hASH1 synthesis. PMID: 25124043
  • ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. PMID: 24037524
  • lentiviral overexpression of transcription factors ASCL1, SOX10, and NKX2.2 in NPCs was sufficient to induce Sox10 enhancer activity, OPC mRNA, and protein expression consistent with OPC fate PMID: 24982138
  • ASCL1 Promotes Wnt Signaling Directly by Repressing DKK1. PMID: 23707066
  • BRN2 is a higher level regulator than ASCL1 and ND1 and BRN2 might be involved in aggressiveness of small cell lung cancer. PMID: 23530560
  • Gene expression profiling revealed that permissive lines are typified by lower expression of the early neurogenic transcription factor ASCL1 and, conversely, by higher expression of the late neurogenic transcription factor NEUROD1. PMID: 23739064
  • ASH1 overexpression in prostate cancer cells promotes neuroendocrine differentiation and increased cell viability. PMID: 23657976
  • Achaete-scute homolog 1 may be proposed as a diagnostic marker of poor differentiation and may help to differentiate neuroendocrine carcinomas from neuroendocrine tumors in difficult cases. PMID: 23375646
  • Ascl1 modulates multiple steps of oligodendrocyte precursor cell development in the postnatal brain and in response to demyelinating insults. PMID: 23739972
  • Ascl1 directly regulates expression of matrix metalloproteinase-7 and O(6)-methylguanine-DNA methyltransferase. PMID: 23300791
  • The ASCL1 knock-down gene set also classified the 171 adenocarcinomas into three subtypes and this NE subtype also had the poorest prognosis. PMID: 21737174
  • Among human primary tumors, 2/2 SCLC, 5/5 pulmonary carcinoids, and 10/41 non-SCLC (only 4 of which had NE features) were positive for hASH1 by immunohistochemistry and RNA-RNA in situ hybridization. PMID: 21684625
  • hASH-1 expression occurs in breast cancers with neuroendocrine differentiation regardless of the extent of the NE cell population, and it is restricted to a subset of tumor cells having a low proliferative potential. PMID: 22422124
  • Dual-luciferase assays showed that ASCL1 activated the expression of miR-375 by binding to the three E-box elements in the miR-375 promoter. These results imply a role of ASCL1 in SCLC via the upregulation of miR-375. PMID: 22172490
  • miR-375 is a key downstream effector of ASH1 function in lung cancer cells PMID: 21856745
  • The present results suggest that a transcriptional complex of LMO3 and HEN2 may contribute to the genesis and malignant phenotype of neuroblastoma by inhibiting HES1 which suppresses the transactivation of Mash1. PMID: 21573214
  • HASH1 down-regulation is associated with cell proliferation, thereby resulting in uterine carcinogenesis. PMID: 21495212
  • ASCL1-pathway is responsible for the up-regulation of IGF2 during neuroblastoma differentiation. PMID: 20842449
  • deletional rearrangement of the TCR delta gene disrupted the hypothetical gene C12orf42 and brought the Achaete-scute complex homolog 1 gene into proximity of the TRA enhancer, which is overexpressed in thyroid and lung cancers PMID: 20659153
  • hASH1 is a new kind of highly specific markers of pulmonary neuroendocrine tumours, and may be applied to clinical pathology diagnosis of the pulmonary neuroendocrine tumors. PMID: 20677557
  • report the analysis of 9 highly conserved putative enhancers in a 64kb interval encompassing the human ASCL1 locus PMID: 20206680
  • Supratentorial PNETs expressed significantly higher levels of SOX2, NOTCH1, ID1, and ASCL-1 transcripts. PMID: 20515335
  • Our data indicate a specific role for ASCL1 in regulating the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus. This regulation may contribute to the predicted role that ASCL1 plays in SCLC tumorigenesis. PMID: 20124469
  • these support the role of the polyglutamine length variants in the MASH1 gene in Parkinson's disease susceptibility. PMID: 20097173
  • HASH1 mRNA expression levels in SCLC clinical samples were 1,000-fold higher than in the NSCLC samples, and this method could contribute to diagnosis based on molecular profiling of tumors. PMID: 11948117
  • We also studied the proneural HASH-1 gene and identified a heterozygous nucleotide substitution in three CCHS patients PMID: 14532329
  • HASH1 appears to be important in the endocrine phenotype of medullary thyroid carcinoma (MTC) tumors and may serve as a molecular target for the treatment of patients with MTC. PMID: 14668716
  • ASH1 is a neuroendocrine marker whose expression is largely conserved in normal and neoplastic pituitary cells. PMID: 14759067
  • the hASH1 mRNA level might represent a useful tool for distinguishing esthesioneuroblastoma from poorly differentiated tumors of the sinonasal region PMID: 15272537
  • Up-Regulation of ASCL1 is associated with gastrointestinal neuroendocrine carcinomas PMID: 15701827
  • The present genetic data may thus suggest that polyglutamine length polymorphisms in ASCL1 could influence predispositions to PD through the fine-tuning of LC integrity. PMID: 16021468
  • RaF-1 activation causes cessation of hASH-1 expression PMID: 16029117
  • Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma PMID: 16103883
  • Knockdown of ASH1 gene in lung neoplasm cells in vitro suppressed growth by increasing apoptosis. PMID: 17507989
  • In prostate cancers with neuroendocrine differentiation...hASH1 transcript levels in androgen deprivation-treated compared with untreated patients PMID: 18311112
  • ASH1 functions as a dual transcription factor by activating neuroendocrine differentiation markers and also repressing putative tumor suppressors. PMID: 18339843
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed